G, it's definitely possible, and it's boubtful by the time the deal would be public that someone somewhere wouldn't have caught on an the stock wouldn't have adjusted closer to a proper range.

ESS in China is worth what it's worth. This product doesn't ever have to get to China, but it may be demanded later when w might have a much higher cap. If they don't feel like we're going bankrupt, they simply pay the price that gets them the asset. Honestly I'd let it go for lower. GC may or may not.

That's why maybe having a diverse pipeline can help. He can hold alternative elto partnership as card to walk away.

And early MANF partnership in China, which remember, Anhui Medical University does MANF research, would be quite the sweetner.